Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0470
-0.0060 (-11.32%)
Mar 26, 2026, 3:20 PM EST
PVCT Revenue
In the year 2025, Provectus Biopharmaceuticals had annual revenue of $336.11K, down -45.54%.
Revenue
336.11K
Revenue Growth
-45.54%
P/S Ratio
59.55
Revenue / Employee
56.02K
Employees
6
Market Cap
20.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 336.11K | -281.03K | -45.54% |
| Dec 31, 2024 | 617.14K | 59.43K | 10.66% |
| Dec 31, 2023 | 557.71K | -431.33K | -43.61% |
| Dec 31, 2022 | 989.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HOOKIPA Pharma | 9.35M |
| Zeo ScientifiX | 5.56M |
| Harvard Apparatus Regenerative Technology | 704.00K |
| Zenith Capital | 500.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 115.29K |
Provectus Biopharmaceuticals News
- 6 months ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer - GlobeNewsWire
- 9 months ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 10 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call - GlobeNewsWire
- 2 years ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire